Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Hledat Study Connect

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents - CN012-0020

Updated: 20 únor, 2026   |   ClinicalTrials.gov

Tisk přehledného shrnutí

ZVAŽUJETE TOTO HODNOCENÍ?
Vytiskněte si tuto stránku a průvodce hodnocením, pomůže vám to při rozhovoru s lékařem.
Pomocí průvodce hodnocením se můžete pohybovat procesem účasti na klinickém hodnocení. Než se rozhodnete, zjistěte si, jaké jsou klíčové faktory, a připravte si otázky pro zdravotnický tým.

Podrobnosti o hodnocení

  • Phase 3

    Fáze

  • Pohlaví

  • 13-17

    Věková skupina

  • 25

    Umístění

  • Recruiting

Možnosti léčby

Ramena studie
Přiřazená léčba
Experimental: KarXT
Drug: KarXT
Placebo Comparator: Placebo
Other: KarXT Matching Placebo

Klíčová kritéria způsobilosti

Inclusion Criteria: - Diagnosis of schizophrenia as defined by the The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,Text Revision (DSM-5-TR) criteria, confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL) and experiencing symptoms of psychosis at screening (Visit 1). - PANSS total score of at least 70 at screening (Visit 1) and randomization (Visit 2). - Participant has a CGI-S score of ≥ 4 at screening (Visit 1) and randomization (Visit 2). Exclusion Criteria: - Any primary DSM-5-TR disorder other than schizophrenia within 12 months before screening. - History or presence of clinically significant cardiovascular, pulmonary, hepatic impairment, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results. - All grades of hepatic impairment (mild [Child-Pugh Class A], moderate [Child-Pugh Class B], and severe [Child-Pugh Class C]). Participants with known intellectual disability defined as an IQ less than 70; or, either clinical evidence or known social or school history indicative of intellectual disability. - Any neurological disorder, except for Tourette's Syndrome. - Participants who have either a systolic blood pressure (sBP) or diastolic blood pressure (dBP) meeting criteria for stage 2 HTN, regardless of the presence or absence of symptoms. - Other protocol-defined Inclusion/Exclusion criteria apply.

Důrazně doporučujeme kontaktovat BMS a oznámit vedlejší účinky / nežádoucí příhody
Zde jsou definovány vedlejší účinky / nežádoucí příhody a další příhody, které by měly být hlášeny
Nahlásit vedlejší účinky / nežádoucí příhody nebo stížnosti na kvalitu produktu: lékařské informace

Máte otázky? Pošlete nám e-mail

Máte otázky?
Pošlete nám e-mail